Neoplasia/BPH

	Visualizing eligibility gaps between muscle-invasive bladder cancer trials and real-world patients. Jpn J Clin Oncol Ichiyama T, Narita T, Sekine Y, Shinohara M, Kawashima Y, Kobayashi M, Numakura K, Mikami J, Fujita N, Okamoto T, Yamamoto H, Narita S, Sato S, Habuchi T, Ohyama C, Hatakeyama S. PMID: 42218684 [PubMed - as supplied by publisher]
	Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial. J Clin Oncol Necchi A, de Jong JJ, Maiorano BA, Proudfoot JA, Basile G, Cigliola A, Mercinelli C, Tateo V, Piacentini M, Crupi E, Pastorino GL, Latini G, Tomasi E, Davicioni E, Moschini M, Brembilla G, Colecchia M, de Cobelli F, Ross JS, Madison R, Tambaoan CFB, Briganti A, Montorsi F. PMID: 42218654 [PubMed - as supplied by publisher]
	Cytoreductive radical prostatectomy in patients with high-volume metastatic prostate cancer achieving deep biochemical response to contemporary systemic therapy: a multicentre, prospective cohort study. BMC Med Huang C, Guo H, Gao W, Huang M, Ji G, Rui R, He S, Yu Y, Zhang N, Tian Y, Niu Y, Li X, Zhou L. PMID: 42218463 [PubMed - as supplied by publisher]
	Exploring the functional role of palmitoylation genes in clear cell renal cell carcinoma and their impact on tumor microenvironment. BMC Genom Data Li J, Chang H, Xu H, Bai Y, Tang W. PMID: 42218414 [PubMed - as supplied by publisher]
	Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review. Target Oncol Yiu CH, Leung GYY, Lee IC, Lu CY. PMID: 42218357 [PubMed - as supplied by publisher]
	Primary site- and metastasis-directed therapies in patients with metastatic prostate cancer: A narrative review. Int J Clin Oncol Goto T, Mizuno K, Sumiyoshi T, Kita Y, Masui K, Ogata T, Aizawa R, Sawada A, Saito R, Mizowaki T, Kobayashi T. PMID: 42218356 [PubMed - as supplied by publisher]
	Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial. Eur Urol Focus Kostos L, Buteau JP, Azad AA, Hofman MS. PMID: 42218070 [PubMed - as supplied by publisher]
	New Paradigms in Theranostics of Prostate Cancer: The Rise of α-Emitters and Next-generation Targets. Eur Urol Focus Deandreis D, Deutsch E. PMID: 42218069 [PubMed - as supplied by publisher]
	Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer. Front Biosci (Landmark Ed) Abou Chakra M, Duquesne I, O'Donnell MA. PMID: 42216552 [PubMed - indexed for MEDLINE]
	Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma. Cancer Med Fukuokaya W, Mori K, Yanagisawa T, Ito K, Imai Y, Urabe F, Rajwa P, Shariat SF, Kimura T, Hirakawa A. PMID: 42216439 [PubMed - indexed for MEDLINE]
	Top advances of the year: Radiopharmaceutical therapy for prostate cancer. Cancer Marulanda-Corzo V, Coraci S, Kakkar P, Okobi TJ, Huicochea-Castellanos S, Osborne JR, Tagawa ST. PMID: 42216431 [PubMed - indexed for MEDLINE]
	Association of DNA damage repair related genes with prostate cancer: A multi-omics Mendelian Randomization analysis. Medicine (Baltimore) Xie H, Ban C, Su Z, Huang Q, Tang H, Cheng Z, Liao T, Liao K, Yi X. PMID: 42216412 [PubMed - indexed for MEDLINE]
	HyperSight(TM)-CBCT based monitoring of sarcopenia during definitive radiotherapy of prostate cancer: a longitudinal feasibility study. Radiat Oncol Siefert V, V Bettenhausen J, Bicu AS, Schmidt R, Willam M, Eckl M, Stieler F, Ehmann M, Buergy D, Fleckenstein J, Beuthien-Baumann B, Schlemmer HP, Froelich MF, Schoenberg SO, Giordano FA, Boda-Heggemann J, Dreher C. PMID: 42216209 [PubMed - indexed for MEDLINE]
	MSTM-Net: a two-stage prostate cancer segmentation network based on swin-transformer-mamba architecture. BMC Med Imaging Chen J, Liu X, Wang S, Ji W. PMID: 42215932 [PubMed - as supplied by publisher]
	Trends and etiological profile of kidney cancer in China from 1990 to 2023: an analysis of modifiable risk factors and prevention implications using GBD 2023 estimates. Int J Clin Oncol Ye Z, Wu H, Zhang C, Wang R, Deng X, Hu E, Wang Z, Gao B. PMID: 42215789 [PubMed - as supplied by publisher]
	Development and validation of a noninvasive machine learning model using urinary extracellular vesicle physical parameters for prostate cancer diagnosis. Sci Rep Jiang K, Pan D, Yu J, Cai W, Zhang B, Wang Z, Lu Y, Wang D, Li X, Zheng D, Wang M, Wang F, Chen J. PMID: 42215604 [PubMed - as supplied by publisher]
	Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol Gontero P, Perry R, Bridge D, Delattre DD, Vosgerau S, Wyn R, Stone M, Babjuk M. PMID: 42215335 [PubMed - as supplied by publisher]
	AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy. Eur Urol Oncol Necchi A, Brembilla G, Whiting K, Arita Y, Akin O, Apte A, Awais M, Lema-Dopico A, Paudyal R, Cosenza M, Maiorano BA, Tateo V, Cigliola A, Mercinelli C, De Cobelli F, Capanu M, Shukla-Dave A, Schwartz LH. PMID: 42215334 [PubMed - as supplied by publisher]
	Dyadic Coping and Its Influencing Factors in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy and Their Spouses: A Latent Class Analysis. J Clin Nurs Chen H, Li Y, He H, Lin H, Song X, Li K. PMID: 42215288 [PubMed - as supplied by publisher]
	Emerging role of urinary biomarkers in bladder cancer diagnosis and prognosis. Urol Oncol Paleru G, Singathala GS, Kural S, Kumar L. PMID: 42214859 [PubMed - as supplied by publisher]

Articles 1 - 20 / 188263

Page 1 of 9414



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy